These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 3922612)

  • 1. Early and delayed clinical cardiotoxicity of doxorubicin.
    Buzdar AU; Marcus C; Smith TL; Blumenschein GR
    Cancer; 1985 Jun; 55(12):2761-5. PubMed ID: 3922612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
    Villani F; Comazzi R; Lacaita G; Guindani A; Genitoni V; Volonterio A; Brambilla MC
    Med Oncol Tumor Pharmacother; 1985; 2(2):93-7. PubMed ID: 3932789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
    Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
    Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer.
    Hardenbergh PH; Recht A; Gollamudi S; Come SE; Hayes DF; Shulman LN; O'Neill A; Gelman RS; Silver B; Harris JR
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):69-72. PubMed ID: 10477008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil v cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: preliminary observations.
    Stewart DJ; Maroun JA; Hirte W; Perrault D; Stolbach L; Cripps C; Lefebvre B
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):23-7. PubMed ID: 6385261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
    Holmes FA; Yap HY; Esparza L; Buzdar AU; Blumenschein GR; Hug V; Hortobagyi GN
    Cancer; 1987 Jun; 59(12):1992-9. PubMed ID: 3567861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
    Diamandidou E; Buzdar AU; Smith TL; Frye D; Witjaksono M; Hortobagyi GN
    J Clin Oncol; 1996 Oct; 14(10):2722-30. PubMed ID: 8874333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
    Hortobagyi GN; Frye D; Buzdar AU; Ewer MS; Fraschini G; Hug V; Ames F; Montague E; Carrasco CH; Mackay B
    Cancer; 1989 Jan; 63(1):37-45. PubMed ID: 2910423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
    J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Colozza M; Tonato M; Grignani F; Davis S
    Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
    Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
    Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin and mitomycin C: possible synergistic cardiotoxicity.
    Buzdar AU; Legha SS; Tashima CK; Hortobagyi GN; Yap HY; Krutchik AN; Luna MA; Blumenschein GR
    Cancer Treat Rep; 1978 Jul; 62(7):1005-8. PubMed ID: 688243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.